Pharmacology
-
Phase 3 TETON trials demonstrate positive results for inhaled treprostinil for IPF
Steven D. Nathan, MD, FCCP, said the evidence shows the drug is effective for treating pulmonary hypertension and may slow or prevent fibrosis progression.
-
Triple therapy shows meaningful benefits in uncontrolled asthma
Alberto Papi, MD, FCCP, said recent data from the KALOS and LOGOS trials suggest triple therapy may address airflow limitation and exacerbation risk in a single inhaler.
-
Umeclidinium-vilanterol shows modest but consistent advantage among LAMA-LABA options in symptomatic COPD
Investigator William B. Feldman, MD, PhD, MPH, said the findings raise important questions about whether inhalers in the same class are indeed therapeutically equivalent for patients with COPD.
-
Data show oral nalbuphine significantly reduces chronic cough in idiopathic pulmonary fibrosis
Experts discuss the promising results—particularly surrounding patient-reported outcomes in this population—and the need for long-term safety data.
-
Study finds triple combination modulator therapy reduces inflammation in CF
Valentino Bezzerri, PhD, discusses findings from a compassionate-use study examining the effects of elexacaftor/tezacaftor/ivacaftor on inflammation in patients with cystic fibrosis.
-
Effects of LAMA or ICS withdrawal may increase risk for COPD exacerbations
Discontinuing LAMA or ICS treatment may more than double the risk of exacerbations for up to 90 days, according to an analysis by Alexander Mathioudakis, MD, PhD.
-
Biologic therapies in asthma: From foundation to the future
Biologic therapies are changing severe asthma management, shifting the goal from control to remission. Diego J. Maselli, MD, FCCP; Dharani Narendra, MD, FCCP; and Megan Conroy, MD, MAEd, FCCP, explore their impact in this installment of Clinical Outlook in Pulmonology.
-
Sotatercept in pulmonary arterial hypertension
Understanding when to consider sotatercept and how to use it has become a critical part of PAH care.
-
GLP-1RAs may trigger chronic cough for some patients with diabetes
Surprisingly, the association between GLP-1 medications and chronic cough was stronger in patients without an existing diagnosis of gastroesophageal reflux disease.
-
GLP-1RAs may reduce risk of asthma exacerbations for adolescents with obesity
Pulmonologist Farrukh Abbas, MD, said this observational study generates a hypothesis about the anti-inflammatory benefits of GLP1-RA medications in patients with asthma and obesity that needs to be confirmed in trials.
